Only two years after the first COVID-19 cases were diagnosed in the United States, scientists have created powerful tools against the virus.
Problem: Hard to get.
“The proliferation of regulatory, testing, and logistic issues complicates deployments, requiring people with symptoms to visit the clinic or testing site multiple times within the five days when the drug is recommended. It’s possible, “says Politico. report on Sunday.
The antiviral COVID-19 pill is “cheaper and more practical than single antibody therapy, which has been shown to be effective against rapidly spreading Omicron variants that must be administered in the clinical setting.” That’s because the series of pills should start within a few days of the onset of symptoms, after tests confirm Covid-19 infection, “said the liberal political website.
“The emergency use authorization for pills is written so that prescribing power is limited to doctors and certain healthcare professionals commonly found in doctors’ practice. It is a testing site just for patients to get the drug. Look for these medicines, which may create an access merry-go-round that may require you to visit a clinic, and a participating pharmacy, “said the site.
The report shows that the CEO of the first company to receive COVID-19 vaccine approval is that the virus is “controlled” by annual vaccinations and tablets to treat the disease when people get sick. After saying that you want it.
Albert Bourla, head of pharmaceutical giant Pfizer, Said At CNBC, annual COVID-19 vaccination may be the norm, as is annual influenza vaccination.
“We are living a perfectly normal life. Perhaps we only inject once a year. And if we get sick, the pill becomes more like a flu than a life-threatening illness. “I will.” However, Bourla added: “Two doses of the vaccine, if any, provide very limited protection.”
The Food and Drug Administration (FDA) approved Pfizer’s COVID-19 treatment at the end of last year, but it has not been widely available so far.
Bourla’s comments reflect those of Stéphane Bancel, CEO of Moderna, which also manufactures vaccines. Bansel also told CNBC that he was looking at additional booster shots as needed to fight the virus. He also determined what his company “is very active in Omicron-specific vaccines as a booster” and “what we consider to be the best strategy for potential boosters in the fall of 2022”. We are discussing with public health leaders around the world to do so. “
“We believe it contains Omicron mRNA,” he said, referring to the genetic engineering used in Moderna’s vaccine. “But do you need other components? You need to be careful to stay ahead of the virus, so we need to discuss it.”
Recent reports show that the risk of being involved in the intensive care unit or dying from the Omicron variant of SARS-CoV-2 is 83% lower than that of the Delta strain. study.. In addition, a Canadian study found that the risk of hospitalization or death from Omicron infection was 65% lower than that of Delta.
Despite the seemingly good news, researchers were still warning. “Although the severity can be reduced, the absolute number of hospitalizations and the impact on the health care system can still be significant due to the increased contagion of the epidemic.”
Joseph Curl covered politics for 35 years, including 12 years as a correspondent for the White House, and carried out the Drudge Report from 2010 to 2015. Please send a hint to josephcurl@ dailywire.com.
The Daily Wire is one of America’s fastest growing and conservative media companies and a counterculture outlet for news, opinion and entertainment.Get internal access to The Daily Wire by becoming member..
